Verrica Pharmaceuticals Inc. (VRCA) stock

VRCANasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 4/30

$3.56−0.16 (-4.30%)

Close on Nov 13, 2026Market cap $61.16MP/E –Yield –

Verrica Pharmaceuticals ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Verrica Pharmaceuticals has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

Parsed from the XBRL in Verrica Pharmaceuticals's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-10 reverse split on Jul 25, 2025
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing